[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"common-cold\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:common-cold":30},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,6,0,[8,43,75,108,141,165],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":17,"sex":18,"minAge":19,"maxAge":20,"enrollmentInfo":21,"targetDuration":4,"studyType":24,"phases":25,"briefSummary":27,"conditions":28,"keywords":4,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":32,"lastUpdatePostDateStruct":33,"startDateStruct":36,"completionDateStruct":38,"leadSponsor":40,"locationsCount":4},"100642225","phase-2-a-novel-cold-and-flu-herbal-blend-for-reducing-the-duration-and-severity-of-the-common-cold-100642225",false,"NCT07642648","A Novel Cold and Flu Herbal Blend for Reducing the Duration and Severity of the Common Cold","A Randomized Blinded Controlled Trial Evaluating the Efficacy of a Novel Herbal Cold and Flu Blend in Reducing the Duration and Severity of Symptoms of the Common Cold","NOURTI","Inclusion Criteria:\n\n* Adults aged 18-65 years living in Australia\n* Individuals with a history of recurrent Upper Respiratory Tract infections (URTI) (at least one episode per year)\n* Able to provide informed consent\n* Generally healthy\n* Agree to not participate in another clinical trial while enrolled in this trial\n* Agree to maintain their usual daily activities without significant changes. This includes not changing their current diet or stopping\u002Fstarting a new exercise regimen during entire study period\n* Females of childbearing potential must use a prescribed form of birth control (e.g. oral contraceptive)\n\nExclusion Criteria:\n\n* Serious illness e.g., liver disease, kidney disease, heart disease, mood disorders, autoimmune conditions, neurological disorders such as multiple sclerosis.\n* Unstable illness e.g., changing medication\u002Ftreatment.\n* BMI \\\u003C18.5, \\>30\n* Current malignancy (excluding Basal Cell Carcinoma) or chemotherapy or radiotherapy treatment for malignancy within the previous 2 years.\n* Individuals with chronic respiratory conditions (e.g., asthma, chronic obstructive pulmonary disease).\n* Active smokers, nicotine use (including vaping\u002Fe-cigarettes) or drug (prescription or illegal substances) abuse\n* Current alcohol use (\\>21 alcoholic drinks week)\n* Allergic to any of the ingredients in the active or placebo formula\n* Allergic to plants in the Asteraceae family\n* Pregnant or lactating woman\n* Regular use of medications that would affect the immune and\u002For the inflammatory response e.g. antihistamines, anti-inflammatories, immunosuppressants, steroids excluding topical steroid use.\n* Use of anticoagulant medications such as warfarin.\n* Participants who are currently participating in any other clinical trial or who have participated in any other clinical trial during the past 1 month\n* Participants with allergic rhinitis\n* Regular use of antihistamines\n* Individuals deemed unsuitable for participation by the Principal Investigator (PI) of this study.",true,"ALL","18 Years","65 Years",{"count":22,"type":23},300,"ESTIMATED","INTERVENTIONAL",[26],"PHASE2","The aim of this study is to evaluate the efficacy of a Novel Herbal Cold \\& Flu Blend in reducing the duration of symptoms of the common cold. The secondary objective is to assess whether the investigational product reduces the severity of symptoms. Participants will be enrolled for 16 weeks, during this period they will take the assigned study product when they experience URTI symptoms.",[29,30],"URTI","Common Cold","NOT_YET_RECRUITING","2026-06-07",{"date":34,"type":35},"2026-06-11","ACTUAL",{"date":37,"type":23},"2026-07",{"date":39,"type":23},"2027-12",{"name":41,"class":42},"RDC Clinical Pty Ltd","INDUSTRY",{"id":44,"slug":45,"hasResults":11,"nctId":46,"briefTitle":47,"officialTitle":48,"acronym":49,"eligibilityCriteria":50,"healthyVolunteers":11,"sex":18,"minAge":51,"maxAge":4,"enrollmentInfo":52,"targetDuration":4,"studyType":54,"phases":4,"briefSummary":55,"conditions":56,"keywords":59,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":65,"lastUpdatePostDateStruct":66,"startDateStruct":68,"completionDateStruct":70,"leadSponsor":72,"locationsCount":74},"100640315","observational-study-of-siropsedal-in-acute-cough-100640315","NCT07625683","Observational Study of SIROPSEDAL in Acute Cough","Prospective Multicenter Before-After Study in Children and Adults Treated for Acute Cough With SIROPSEDAL","SIROPSEDAL","Inclusion Criteria:\n\n* Age greater than or equal to 1 year.\n* Acute cough evolving for less than 10 days.\n* Cough intensity VAS greater than 40\u002F100.\n* SIROPSEDAL prescribed independently from study participation.\n* No hospitalization required.\n* Written informed consent from the patient or from parent(s)\u002Flegal representative for minors, as applicable.\n* Able to attend the Day 7 +\u002F- 1 day visit or teleconsultation.\n* Affiliated with or beneficiary of a health insurance system.\n\nExclusion Criteria:\n\n* ACE inhibitor or sartan use.\n* Asthma or COPD.\n* Corticosteroids ongoing or within the previous 3 days.\n* Antibiotics ongoing or within the previous 3 days.\n* Antitussives ongoing or within the previous 3 days.\n* Antihistamines ongoing or within the previous 3 days.\n* Aerosol therapy ongoing or within the previous 3 days.\n* Severe signs suggesting a causal disease requiring additional investigations according to the investigator.\n* Severe signs requiring corticosteroids, aerosol therapy or centrally acting antitussive treatment according to the investigator.\n* Any contraindication listed in the instructions for use.\n* Patient under legal protection.\n* Pregnancy.\n* Intolerance, hypersensitivity or allergy to one or more product components.","1 Year",{"count":53,"type":23},124,"OBSERVATIONAL","This prospective, multicenter, observational post-market clinical follow-up study evaluates the performance and safety of SIROPSEDAL in children and adults with acute cough treated in routine clinical practice. Patients prescribed SIROPSEDAL independently of study participation will be followed for 7 +\u002F- 1 days using patient-reported outcomes including a cough visual analog scale and the Cough Symptom Score.",[57,58,30],"Acute Cough","Upper Respiratory Tract Infection",[60,61,62,63,64],"acute cough","cough","cough syrup","PMCF","Cough Symptom Score","2026-06-02",{"date":67,"type":35},"2026-06-04",{"date":69,"type":23},"2026-10-15",{"date":71,"type":23},"2027-09-30",{"name":73,"class":42},"Laboratoires Elerte",1,{"id":76,"slug":77,"hasResults":11,"nctId":78,"briefTitle":79,"officialTitle":80,"acronym":81,"eligibilityCriteria":82,"healthyVolunteers":11,"sex":18,"minAge":83,"maxAge":4,"enrollmentInfo":84,"targetDuration":4,"studyType":54,"phases":4,"briefSummary":86,"conditions":87,"keywords":92,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":102,"lastUpdatePostDateStruct":103,"startDateStruct":104,"completionDateStruct":105,"leadSponsor":107,"locationsCount":74},"100637983","observational-study-of-rhinosedal-in-acute-nasal-obstruction-100637983","NCT07620522","Observational Study of RHINOSEDAL in Acute Nasal Obstruction","Prospective Multicenter Before-After Study in Children and Adults Treated for Acute Nasal Obstruction With RHINOSEDAL","RHINOSEDAL","Inclusion Criteria:\n\n* Age 8 years or older.\n* Acute nasal obstruction evolving for less than 48 hours associated with common cold, allergic or non-allergic rhinitis, or rhinosinusitis.\n* Baseline NOSE score \\>40\u002F100.\n* No warning signs such as pus, unilateral obstruction, bleeding, or pain.\n* RHINOSEDAL prescribed by the investigator.\n* Written informed consent signed.\n* Affiliated with a health insurance system.\n\nExclusion Criteria:\n\n* Known anatomical cause of chronic nasal congestion.\n* Corticosteroid use within the previous 2 days.\n* NSAID use within the previous 2 days.\n* Sympathomimetic use within the previous 2 days.\n* Nasal decongestant or nasal irrigation within the previous 2 days.\n* Antihistamines unless stable for more than 48 hours and maintained.\n* Contraindication listed in the RHINOSEDAL instructions for use.\n* Patient under legal protection.\n* Pregnant or breastfeeding women.","8 Years",{"count":85,"type":23},126,"This prospective, multicenter, national, observational, non-interventional post-market clinical follow-up study evaluates the performance and safety of RHINOSEDAL in children and adults presenting with acute nasal obstruction associated with common cold, allergic or non-allergic rhinitis, or rhinosinusitis. Patients prescribed RHINOSEDAL in routine care will be followed for 6 ±1 days using patient-reported outcome measures including the NOSE score.",[88,30,89,90,91],"Nasal Obstruction","Allergic Rhinitis","Non-allergic Rhinitis","Rhinosinusitis",[93,94,95,96,97,98,99,100,63,101],"nasal obstruction","NOSE score","rhinitis","rhinosinusitis","common cold","nasal congestion","saline irrigation","medical device","real-world evidence","2026-05-27",{"date":65,"type":35},{"date":69,"type":23},{"date":106,"type":23},"2027-12-31",{"name":73,"class":42},{"id":109,"slug":110,"hasResults":11,"nctId":111,"briefTitle":112,"officialTitle":112,"acronym":113,"eligibilityCriteria":114,"healthyVolunteers":11,"sex":18,"minAge":115,"maxAge":116,"enrollmentInfo":117,"targetDuration":4,"studyType":54,"phases":4,"briefSummary":119,"conditions":120,"keywords":123,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":131,"lastUpdatePostDateStruct":132,"startDateStruct":134,"completionDateStruct":136,"leadSponsor":138,"locationsCount":140},"100612718","post-market-clinical-follow-up-study-of-an-isotonic-saline-solution-to-manage-nasal-congestion-in-case-of-flu-symptoms-colds-allergic-rhinitis-and-rhinosinusitis-in-infants-and-toddlers-100612718","NCT07257224","Post-market Clinical Follow-up Study of an Isotonic Saline Solution to Manage Nasal Congestion in Case of Flu Symptoms, Colds, Allergic Rhinitis and Rhinosinusitis in Infants and Toddlers","Nasal Baby","Inclusion Criteria:\n\n* Male and female infants \u002F toddlers aged 3 to 48 months (inclusive) at the time of enrolment.\n* Subjects with flu, cold, allergic rhinitis or rhinosinusitis as reported by their legal guardian(s) and\u002For medical history.\n* Subjects presenting at least moderately bothersome nasal congestion (blocked or stuffy nose) as reported by their legal guardian(s) and\u002For medical history and confirmed by the site investigator through non-diagnostic inspection.\n* Subjects suitable for nasal hygiene treatment with the study device according to its IFU.\n* Subjects with nasal congestion symptoms that began within 48 hours prior to enrolment.\n* Subjects whose legal guardian(s) signed written informed consent on their behalf to participate in the study.\n* Subject whose legal guardian(s) are willing and able to follow the IFU and comply with all study procedures.\n\nExclusion Criteria (if any severe symptoms are seen in the subject, the guardian will be advised to seek medical evaluation by the subject's physician):\n\n* Subjects with known hypersensitivity or intolerance to seawater or any of its natural mineral components (e.g., sodium, chloride, magnesium) as reported by their legal guardian(s) and\u002For medical history.\n* Subjects showing severe symptoms such as persistent fever (\\>38°C), severe cough, ear pain, or respiratory distress, as reported by their legal guardian(s) and\u002For medical history.\n* Subjects whose legal guardian(s) and\u002For medical history report any ongoing medical diagnosis or treatment for acute infection or chronic respiratory disease (e.g., asthma, pneumonia, laryngotracheobronchitis, sinusitis, etc.).\n* Subjects whose legal guardians(s) and\u002For medical history report any type of immunodeficiency.\n* Subjects whose legal guardian(s) and\u002For medical history report a neurological condition that may affect respiratory functioning.\n* Subjects with visible nasal injury, wounds or bleeding, or any condition that may contraindicate the use of the study device according to the device IFU.\n* Subjects who are currently participating or have participated in another clinical investigation within the last 30 days prior to enrolment.\n* Subjects using saline nasal drops or nasal sprays or pumps other than the study product within 12 hours prior to the time of enrolment or during the study.\n* Subjects using the study product within 24 hours prior to the time of enrolment in the study.\n* Subject using antibiotics, antivirals, intranasal medications, decongestants, antihistamines, mucolytics, echinacea, combination cold formulas, supplements containing ≥ 10 mg zinc that could influence symptom scores within 12 hours prior to the time of enrolment or during the study.","3 Months","48 Months",{"count":118,"type":23},83,"The goal of this observational post-market clinical follow-up study is to evaluate the safety and performance of the CE-marked nasal spray in the management of nasal congestion in case of flu, colds, allergic rhinitis and rhinosinusitis in infants and toddlers aged 3 to 48 months at day 5 post-enrolment. Enrolment does not require establishing a medical diagnosis; eligibility is based on guardian-reported nasal congestion consistent with lay use of the device.\n\nParticipants will be:\n\n* Evaluated by a healthcare professional for eligibility.\n* Receive treatment with the CE-marked nasal spray according to its Instructions for Use, for up to 14 days.\n* Have their legal guardians report symptom severity and improvement using standardized scales (Visual Analog Scale) during follow-up visits on Day 2, Day 5, and Day 14 and device usability on Day 14.\n\nThis study does not include a comparison group and reflects real-world use of the device in routine pediatric care.",[121,30,89,91,122],"Nasal Congestion","Flu Symptom",[124,125,126,127,128,129,130],"infants","toddlers","Upper Respiratory Tract Infections","Pediatric nasal spray","nasal spray","Seawater isotonic solution","Post-market clinical follow-up (PMCF)","2025-11-20",{"date":133,"type":35},"2025-12-02",{"date":135,"type":23},"2025-12",{"date":137,"type":23},"2026-11",{"name":139,"class":42},"Laboratoires Quinton International S.L.",2,{"id":142,"slug":143,"hasResults":11,"nctId":144,"briefTitle":145,"officialTitle":146,"acronym":4,"eligibilityCriteria":147,"healthyVolunteers":11,"sex":18,"minAge":19,"maxAge":20,"enrollmentInfo":148,"targetDuration":4,"studyType":24,"phases":150,"briefSummary":152,"conditions":153,"keywords":4,"overallStatus":154,"whyStopped":4,"lastUpdateSubmitDate":155,"lastUpdatePostDateStruct":156,"startDateStruct":158,"completionDateStruct":160,"leadSponsor":162,"locationsCount":164},"100569718","phase-3-a-study-of-the-efficacy-and-safety-of-antiwei-granules-in-the-treatment-of-common-cold-100569718","NCT06697886","A Study of the Efficacy and Safety of Antiwei Granules in the Treatment of Common Cold","To Evaluate the Efficacy and Safety of Antiwei Granules in the Treatment of Common Cold (Wind-cold Syndrome) in a Multicenter, Randomized, Double-blind, Placebo-controlled Phase Ⅲ Clinical Trial","Inclusion Criteria:\n\n1. It met the diagnostic criteria of common cold in western medicine;\n2. In accordance with the TCM syndrome differentiation standard of wind-cold syndrome;\n3. Male and female patients aged 18 to 65 years;\n4. The disease duration at enrollment was ≤48 h;\n5. At enrollment, 37.3 ° C ≤axillary temperature \\\u003C 38.5 ° C;\n6. Informed consent was obtained voluntarily.\n\nExclusion Criteria:\n\n1. Complicated with influenza, pneumonia, suppurative tonsillitis, acute tracheobronchitis, acute pharyngeal conjunctivitis, acute viral or herpetic pharyngitis, acute viral or herpetic laryngitis;\n2. Patients who had been infected with 2019-ncov in the past and still had symptoms such as cough and fatigue for nearly 3 months after the antigen turned negative;\n3. Primary ciliary dyskinesia syndrome, other acute onset nasal diseases (such as allergic rhinitis, chronic rhinitis, acute and chronic sinusitis, etc.), previous nasal surgery or radiotherapy of the nasopharynx with nasal mucosal dysfunction；\n4. Patients with chronic respiratory diseases (such as chronic obstructive pulmonary disease, interstitial lung disease, etc.), asthma, and tuberculosis;\n5. White blood cell count \\>12.0×10\\^9\u002FL or \\\u003C3.0×10\\^9\u002FL , And\u002For neutrophil percentage \\>80%;\n6. Aspartate aminotransferase and\u002For alanine aminotransferase ≥ 1.5 × ULN, or serum creatinine ≥ ULN, judged by the investigator to be clinically significant；\n7. Combined with other serious primary diseases of the heart, brain, lung, liver, kidney or blood system, such as unstable control\u002Fserious complications of diabetes, viral hepatitis, hemophilia, or mental disorders;\n8. Patients who had been treated with Chinese and western drugs for the relief of common cold and its symptoms after the onset of the current illness, including but not limited to antibiotics, antiviral, antihistamine, steroids, decongestants, antipyretic and analgesic, antitussive and expectorant drugs etc;\n9. Those who were allergic to the known composition of the investigational drug or to emergency medication, or emergency drug contraindication population;\n10. The participants (and their partners) had planned pregnancy or were unwilling to take appropriate contraceptive measures from enrollment to 1 month after the end of the trial, or were pregnant or lactating;\n11. Suspected or true history of alcohol or drug abuse;\n12. Participants who had participated in another clinical trial within 1 month before enrollment;\n13. Persons deemed unsuitable for clinical trial by the investigator (e.g., athletes or persons not eligible for enrollment for other reasons).",{"count":149,"type":23},480,[151],"PHASE3","To further evaluate the efficacy and safety of Antiwei granule in the treatment of common cold (wind-cold syndrome)",[30],"RECRUITING","2024-11-18",{"date":157,"type":35},"2024-11-20",{"date":159,"type":35},"2023-11-16",{"date":161,"type":23},"2025-07-01",{"name":163,"class":42},"Tasly Pharmaceutical Group Co., Ltd",24,{"id":166,"slug":167,"hasResults":11,"nctId":168,"briefTitle":169,"officialTitle":170,"acronym":4,"eligibilityCriteria":171,"healthyVolunteers":11,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":172,"targetDuration":4,"studyType":24,"phases":174,"briefSummary":175,"conditions":176,"keywords":177,"overallStatus":154,"whyStopped":4,"lastUpdateSubmitDate":181,"lastUpdatePostDateStruct":182,"startDateStruct":184,"completionDateStruct":186,"leadSponsor":188,"locationsCount":74},"100556945","phase-3-efficacy-and-safety-in-the-combination-of-ibuprofen--loratadine-versus-ibuprofen-versus-loratadine-100556945","NCT06531707","Efficacy and Safety in the Combination of Ibuprofen \u002F Loratadine Versus Ibuprofen Versus Loratadine","Efficacy and Safety of Ibuprofen\u002FLoratadine Fixed-dose Combination Versus the Fixed-dose Administration of Monotherapy as Symptomatic Treatment for Patients With the Common Cold","Inclusion Criteria:\n\n* Agree to participate in the study and give written informed consent\n* At least 6 points on the Jackson scale according to physical examination and questioning (sneezing, runny nose, nasal obstruction, sore throat, cough, headache, malaise, and chills).\n* Symptoms associated with the common cold with maximum of 3 days since presentation\n* Women of childbearing potential under a medically acceptable method of contraception\n* At the discretion of the Principal Investigator (PI) or treating physician, treatment with the researching product is indicated and may present clinical benefit\n\nExclusion Criteria:\n\n* Patients in whom respiratory symptoms are suspected to be of bacterial origin and generate a clinical picture compatible with: Rhinosinusitis (muco-purulent discharge, headache or facial pain, etc.), lower respiratory tract disease (wheezing, crackles, productive cough, etc.), acute otitis media (otalgia, purulent discharge from the ear, auditory discomfort, etc.).\n* Patients participating in another clinical trial involving an investigational treatment or participation in one within 4 weeks prior to study start\n* Patients in whom participation in the study may be influenced (employment relationship with the research site or sponsor, inmates, etc.)\n* At medical discretion, a disease that affects prognosis and prevents outpatient management, for example, but not limited to: end-stage cancer, kidney, heart, respiratory or liver failure, mental illness or with scheduled surgical or hospital procedures\n* History\u002Fpresence of any disease or condition that, in the opinion of the Investigator, could pose a risk for the patient or confusing the efficacy and safety of the investigational product\n* Patients in whom the study drug is contraindicated for medical reasons\n* Patients with allergy or hypersensitivity to the active substance of the study drugs, related products or excipients (Ibuprofen of Loratadine)\n* Pregnant women, women breastfeeding or planning a pregnancy during the conducting the study\n* Significant history of gastrointestinal diseases (e.g., gastric ulcer, Crohn's disease, Ulcerative Colitis, etc.)\n* History of chronic liver failure Child-Pugh A, B, and\u002For C\n* History of acute renal failure (glomerular filtration rate \\\u003C30 ml\u002Fmin\u002F1.72 m2)\n* Patients with a history of alcohol or drug abuse in the last year\n* Patients with symptoms suggestive of COVID-19 infection (fever, cough, dyspnea) and\u002For contact in the last 14 days with a suspected or positive patient for COVID-19",{"count":173,"type":23},177,[151],"Phase III longitudinal, multicenter, randomized, double-blind clinical trial. The aim of this study is to evaluate the efficacy and safety of the drug combination of Ibuprofen\u002FLoratadine versus Ibuprofen versus Loratadine as monotherapy for the symptomatic treatment of the common cold.",[30],[30,178,179,180],"Flu","Ibuprofen","Loratadine","2024-07-31",{"date":183,"type":35},"2024-08-02",{"date":185,"type":35},"2024-05-20",{"date":187,"type":23},"2025-02-20",{"name":189,"class":42},"Laboratorios Silanes S.A. de C.V."]